ClinicalTrials.gg
CompletedNCT02601625Updated Feb 26, 2019Results posted

A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects

A Phase 1 interventional study of Anifrolumab SC injection (300mg) and Anifrolumab IV infusion (300mg) in Safety, Pharmacokinetics and Healthy Subjects, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-26.

Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a Phase I, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Pharmacokinetics and Safety of anifrolumab following Single-Dose administration to healthy subjects

Read the detailed description

This is a Phase I placebo-controlled study to assess the pharmacokinetics, safety and tolerability of 2 doses of anifrolumab via the subcutaneous (SC) route of administration and 1 dose of anifrolumab via intravenous (IV) route in healthy subjects

02

Conditions studied

  • Safety
  • Pharmacokinetics
  • Healthy Subjects

Keywords

  • Tolerability
  • Anifrolumab
  • Subcutaneous injection
  • Intravenous infusion
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated, written prior to any study specific procedures.
  2. Healthy male and/or female subjects aged 18 - 55 years.
  3. Females must have a negative pregnancy test at screening.
  4. Females with an intact cervix must have documentation of a Pap smear with no documented .
  5. Have a (BMI) between 18 and 32 kg/m2, inclusive, and weigh at least 50 kg.
  6. Must have adequate abdominal adipose tissue for SC injection.
  7. No history of latent or active TB prior to screening.
  8. A chest radiograph with no evidence of current active infection or old active TB, malignancy, or abnormalities within 6 months prior to screening.

Exclusion criteria

Exclusion Criteria:

  1. History of any disease or disorder which may put the subject at risk .
  2. History or presence of hepatic or renal disease.
  3. Any clinically significant illness, medical/surgical procedure, or trauma within 8 weeks of participation .
  4. Any clinically significant chronic or recent infection requiring hospitalization or treatment with anti-infectives.
  5. History of cancer, apart from squamous or basal cell carcinoma of the skin.
  6. Any clinically significant lab, vital sign or abnormalities as judged by the investigator.
  7. Known history of a primary immunodeficiency, splenectomy or an underlying condition.
  8. Any positive result on screening for , or HIV antibody.
  9. History of drug abuse within 1 year of participation.
  10. Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 4 weeks or 5 half-lives prior to participation.
  11. Previous receipt of:

    • Anifrolumab;
    • B cell-depleting therapy (including but not limited to epratuzumab, ocrelizumab, or rituximab) ≤ 52 weeks prior to screening.
  12. History of allergy/ to drugs with a similar chemical structure or class to anifrolumab or to any human gamma globulin therapy.
  13. Any live or attenuated vaccine within 8 weeks prior to participation.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Anifrolumab 300 mg SC injections

    300 mg single dose anifrolumab delivered as 2 separate 1 mL SC injections administered serially

    Drug: Anifrolumab SC injection (300mg)

  • Experimental
    Anifrolumab 300 mg IV infusion

    300 mg single dose anifrolumab delivered as an IV infusion over 30 minutes

    Drug: Anifrolumab IV infusion (300mg)

  • Experimental
    Anifrolumab 600 mg SC infusion

    600 mg single dose anifrolumab or placebo delivered as 4 mL SC by infusion pump

    Drug: Anifrolumab SC infusion (600mg)

  • Placebo comparator
    Placebo 300 mg SC injections

    300 mg single dose placebo delivered as 2 separate 1 mL SC injections administered serially

    Drug: Anifrolumab placebo SC injection (300mg)

  • Placebo comparator
    Placebo 300 mg IV infusion

    300 mg single dose placebo delivered as an IV infusion over 30 minutes

    Drug: Anifrolumab placebo IV infusion (300mg)

  • Placebo comparator
    Placebo 600mg SC infusion

    600 mg single dose placebo delivered as 4 mL SC by infusion pump

    Drug: Anifrolumab placebo SC infusion (600mg)

Interventions

  • 300 mg of anifrolumab delivered as 2 separate 1 mL SC injections administered serially on Day 1

  • 300 mg of anifrolumab delivered as an IV infusion over 30 minutes on Day 1

  • 600 mg of anifrolumab delivered as 4 mL SC by infusion pump on Day 1

  • DrugAnifrolumab placebo SC injection (300mg)

    300mg of placebo delivered as 2 separate 1 mL SC injections administered serially on Day 1

  • DrugAnifrolumab placebo IV infusion (300mg)

    600mg of placebo delivered as an IV infusion over 30 minutes on Day 1

  • DrugAnifrolumab placebo SC infusion (600mg)

    600 mg of placebo delivered as 4 mL SC by infusion pump on Day 1

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: Observed Maximum Serum Concentration (Cmax) Following Single Dose of Anifrolumab.

    To evaluate Cmax of anifrolumab after single administration of two doses subcutaneously and one dose intravenously. Up to 13 blood samples were collected in total.

    Time frame: On Day 1 pre-dose and at 5 minutes (IV cohort only), 24 and 48 hours post-dose and at each follow-up visit, up to 85 days

  2. Pharmacokinetics: Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) Following Single Dose of Anifrolumab

    To evaluate AUC(0-t) of anifrolumab after single administration of two doses subcutaneously and one dose intravenously Up to 13 blood samples were collected in total.

    Time frame: On Day 1 pre-dose and at 5 minutes (IV cohort only), 24 and 48 hours post-dose and at each follow-up visit, up to 85 days

  3. Pharmacokinetics: Area Under Serum Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC) Following Single Dose of Anifrolumab

    To evaluate AUC of anifrolumab after single administration of two doses subcutaneously and one dose intravenously. Up to 13 blood samples were collected in total.

    Time frame: On Day 1 pre-dose and at 5 minutes (IV cohort only), 24 and 48 hours post-dose and at each follow-up visit, up to 85 days

  4. Safety: Number of Participants With Adverse Events (AEs)

    To assess the safety and tolerability of single doses of anifrolumab

    Time frame: From screening to final follow-up visit, up to 16 weeks

  5. Safety: Summary of Local Injection Site Pain (SC Cohorts) Assessed in Participants

    Local injection site pain was assessed using a 100 mm participant rated Visual Analog Scale (VAS 0mm - 100mm ungraduated scale, where 0 = "no pain" to 100 = "worst imaginable pain"). This assessment was taken for only those participants in subcutaneously dosed treatment groups; 600 mg SC and 300 mg SC, anifrolumab and placebo. For the 300 mg SC anifrolumab and 300 mg SC placebo groups which received two simultaneous injections, the average VAS score (0mm-100mm) of the two injection sites were reported.

    Time frame: Immediately after dosing, at 10, 20 minutes and 1 hour after injection

  6. Safety: Summary of Local Injection Site Pruritus (SC Cohorts) Assessed in Participants

    Local injection site pruritus was assessed using a 100 mm participant rated Visual Analog Scale (VAS 0mm - 100mm ungraduated scale, where 0 = "no itching" to 100 = "worst imaginable itching"). This assessment was taken for only those participants in subcutaneously dosed treatment groups; 600 mg SC and 300 mg SC, anifrolumab and placebo. For the 300 mg SC anifrolumab and 300 mg SC placebo groups which received two simultaneous injections, the average VAS score (0mm-100mm) of the two injection sites were reported.

    Time frame: Immediately after dosing, at 10, 20 minutes and 1 hour after injection

  7. Safety: Summary of Erythema Injection Site Reaction (SC Cohorts) Assessed in Participants

    Erythema was measured as the largest diameter across the needle site on the skin in millimetres (mm). This assessment was taken for only those participants in subcutaneously dosed treatment groups; 600 mg SC and 300 mg SC, anifrolumab and placebo. For the 300 mg SC anifrolumab and 300 mg SC placebo groups which received two simultaneous injections, the average of the two injection site diameters (mm) were reported.

    Time frame: Immediately after dosing, at 10, 20 minutes and 1 hour after injection

  8. Safety: Summary of the Induration Injection Site Reaction (SC Cohorts) Assessed in Participants

    Induration was measured as the largest diameter across the needle site on the skin in millimetres (mm). This assessment was taken for only those participants in subcutaneously dosed treatment groups; 600 mg SC and 300 mg SC, anifrolumab and placebo. For the 300 mg SC anifrolumab and 300 mg SC placebo groups which received two simultaneous injections, the average of the two injection site diameters (mm) were reported.

    Time frame: Immediately after dosing, at 10, 20 minutes and 1 hour after injection

Secondary outcomes

  1. Evaluation of Immunogenicity of Anifrolumab IV Infusions and SC Injections by the Measurement of Anti-drug Antibody (ADA).

    Immunogenicity was assessed in all groups by the presence or absence of ADA, which was determined in serum samples using validated bioanalytical methods. The reported results are based on the confirmatory assay (positive/negative) of the ADA. The number of participants with positive, negative and missing results are reported for each time point using the safety analysis set.

    Time frame: Pre-dose and at Days 5 and Day 29, up to 85 days

07

Results

Posted Feb 26, 2019

Participant flow

This study was conducted at the PAREXEL Early Phase Clinical Unit Baltimore, 3001 S. Hanover St. Baltimore, MD 21225 United States of America

Participant flow — Overall Study
MilestoneAnifrolumab 300 mg SC InjectionsAnifrolumab 300 mg IV InfusionAnifrolumab 600 mg SC InfusionPooled Placebo
Started66612
Completed66511
Not completed0011
Withdrew: Lost to follow-up0011

Outcome measures

PrimaryPharmacokinetics: Observed Maximum Serum Concentration (Cmax) Following Single Dose of Anifrolumab.

To evaluate Cmax of anifrolumab after single administration of two doses subcutaneously and one dose intravenously. Up to 13 blood samples were collected in total.

Time frame:
On Day 1 pre-dose and at 5 minutes (IV cohort only), 24 and 48 hours post-dose and at each follow-up visit, up to 85 days
Reported as:
Mean · ug/mL
Pharmacokinetics: Observed Maximum Serum Concentration (Cmax) Following Single Dose of Anifrolumab.
ug/mLAnifrolumab 300 mg SC InjectionsAnifrolumab 300 mg IV InfusionAnifrolumab 600 mg SC Infusion
Pharmacokinetics: Observed Maximum Serum Concentration (Cmax) Following Single Dose of Anifrolumab.36.22 ± 11.6382.44 ± 13.1663.86 ± 20.45
PrimaryPharmacokinetics: Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) Following Single Dose of Anifrolumab

To evaluate AUC(0-t) of anifrolumab after single administration of two doses subcutaneously and one dose intravenously Up to 13 blood samples were collected in total.

Time frame:
On Day 1 pre-dose and at 5 minutes (IV cohort only), 24 and 48 hours post-dose and at each follow-up visit, up to 85 days
Reported as:
Mean · day*μg/mL
Pharmacokinetics: Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) Following Single Dose of Anifrolumab
day*μg/mLAnifrolumab 300 mg SC InjectionsAnifrolumab 300 mg IV InfusionAnifrolumab 600 mg SC Infusion
Pharmacokinetics: Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) Following Single Dose of Anifrolumab769.1 ± 336.9902.9 ± 175.81639 ± 557.7
PrimaryPharmacokinetics: Area Under Serum Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC) Following Single Dose of Anifrolumab

To evaluate AUC of anifrolumab after single administration of two doses subcutaneously and one dose intravenously. Up to 13 blood samples were collected in total.

Time frame:
On Day 1 pre-dose and at 5 minutes (IV cohort only), 24 and 48 hours post-dose and at each follow-up visit, up to 85 days
Reported as:
Mean · day*μg/mL
Pharmacokinetics: Area Under Serum Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC) Following Single Dose of Anifrolumab
day*μg/mLAnifrolumab 300 mg SC InjectionsAnifrolumab 300 mg IV InfusionAnifrolumab 600 mg SC Infusion
Pharmacokinetics: Area Under Serum Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC) Following Single Dose of Anifrolumab784.6 ± 330.6906.5 ± 174.91828 ± 679.8
PrimarySafety: Number of Participants With Adverse Events (AEs)

To assess the safety and tolerability of single doses of anifrolumab

Time frame:
From screening to final follow-up visit, up to 16 weeks
Reported as:
Number · Participants
Safety: Number of Participants With Adverse Events (AEs)
ParticipantsAnifrolumab 300 mg SC InjectionsAnifrolumab 300 mg IV InfusionAnifrolumab 600 mg SC InfusionPooled PlaceboPlacebo 300 mg Anifrolumab SCPlacebo 600 mg Anifrolumab SCPlacebo 300 mg Anifrolumab IVAll Anifrolumab Participants
Safety: Number of Participants With Adverse Events (AEs)32441219
PrimarySafety: Summary of Local Injection Site Pain (SC Cohorts) Assessed in Participants

Local injection site pain was assessed using a 100 mm participant rated Visual Analog Scale (VAS 0mm - 100mm ungraduated scale, where 0 = "no pain" to 100 = "worst imaginable pain"). This assessment was taken for only those participants in subcutaneously dosed treatment groups; 600 mg SC and 300 mg SC, anifrolumab and placebo. For the 300 mg SC anifrolumab and 300 mg SC placebo groups which received two simultaneous injections, the average VAS score (0mm-100mm) of the two injection sites were reported.

Time frame:
Immediately after dosing, at 10, 20 minutes and 1 hour after injection
Reported as:
Mean · Millimeter
Safety: Summary of Local Injection Site Pain (SC Cohorts) Assessed in Participants
MillimeterAnifrolumab 300 mg SC InjectionsAnifrolumab 600 mg SC InfusionPlacebo 300 mg Anifrolumab SCPlacebo 600 mg Anifrolumab SC
Immediately after dosing1.2 ± 2.210.0 ± 0.008.0 ± 13.690.0 ± 0.00
10 min after injection0.5 ± 0.630.0 ± 0.000.5 ± 1.000.0 ± 0.00
20 min after injection0.3 ± 0.420.0 ± 0.000.4 ± 0.750.3 ± 0.50
1 hour after injection0.2 ± 0.410.0 ± 0.000.3 ± 0.500.0 ± 0.00
PrimarySafety: Summary of Local Injection Site Pruritus (SC Cohorts) Assessed in Participants

Local injection site pruritus was assessed using a 100 mm participant rated Visual Analog Scale (VAS 0mm - 100mm ungraduated scale, where 0 = "no itching" to 100 = "worst imaginable itching"). This assessment was taken for only those participants in subcutaneously dosed treatment groups; 600 mg SC and 300 mg SC, anifrolumab and placebo. For the 300 mg SC anifrolumab and 300 mg SC placebo groups which received two simultaneous injections, the average VAS score (0mm-100mm) of the two injection sites were reported.

Time frame:
Immediately after dosing, at 10, 20 minutes and 1 hour after injection
Reported as:
Mean · Millimeter
Safety: Summary of Local Injection Site Pruritus (SC Cohorts) Assessed in Participants
MillimeterAnifrolumab 300 mg SC InjectionsAnifrolumab 600 mg SC InfusionPlacebo 300 mg Anifrolumab SCPlacebo 600 mg Anifrolumab SC
Immediately after dosing1.3 ± 2.6014.0 ± 20.291.3 ± 1.660.8 ± 0.96
10 min after injection0.7 ± 1.216.3 ± 14.560.6 ± 1.250.0 ± 0.00
20 min after injection0.3 ± 0.521.5 ± 3.670.5 ± 1.000.3 ± 0.50
1 hour after injection0.1 ± 0.200.0 ± 0.000.4 ± 0.750.0 ± 0.00
PrimarySafety: Summary of Erythema Injection Site Reaction (SC Cohorts) Assessed in Participants

Erythema was measured as the largest diameter across the needle site on the skin in millimetres (mm). This assessment was taken for only those participants in subcutaneously dosed treatment groups; 600 mg SC and 300 mg SC, anifrolumab and placebo. For the 300 mg SC anifrolumab and 300 mg SC placebo groups which received two simultaneous injections, the average of the two injection site diameters (mm) were reported.

Time frame:
Immediately after dosing, at 10, 20 minutes and 1 hour after injection
Reported as:
Mean · Millimeter
Safety: Summary of Erythema Injection Site Reaction (SC Cohorts) Assessed in Participants
MillimeterAnifrolumab 300 mg SC InjectionsAnifrolumab 600 mg SC InfusionPlacebo 300mg SC InjectionPlacebo 600 mg SC Injection
Immediately after dosing0.3 ± 0.4217.0 ± 19.7511.5 ± 14.6220.0 ± 13.54
10 minutes after injection2.0 ± 4.1817.5 ± 21.395.1 ± 9.5918.0 ± 14.99
20 minute after injection2.7 ± 4.1416.6 ± 20.815.5 ± 9.1126.0 ± 18.55
1 hour after injection0.3 ± 0.522.5 ± 6.120.3 ± 0.5010.0 ± 14.14
SecondaryEvaluation of Immunogenicity of Anifrolumab IV Infusions and SC Injections by the Measurement of Anti-drug Antibody (ADA).

Immunogenicity was assessed in all groups by the presence or absence of ADA, which was determined in serum samples using validated bioanalytical methods. The reported results are based on the confirmatory assay (positive/negative) of the ADA. The number of participants with positive, negative and missing results are reported for each time point using the safety analysis set.

Time frame:
Pre-dose and at Days 5 and Day 29, up to 85 days
Reported as:
Number · Participants
Evaluation of Immunogenicity of Anifrolumab IV Infusions and SC Injections by the Measurement of Anti-drug Antibody (ADA).
ParticipantsAnifrolumab 300 mg SC InjectionsAnifrolumab 300 mg IV InfusionAnifrolumab 600 mg SC InfusionPooled PlaceboAll Subjects
Day 1, pre-dose (positive)00000
Day 1, pre-dose (negative)6661230
Day 1, pre-dose (missing)00000
Day 5 (positive)00000
Day 5 (negative)6661230
Day 5 (missing)00000
Day 29 (positive)00000
Day 29 (negative)6651128
Day 29 (missing)00112
Day 85 (positive)01001
Day 85 (negative)6551127
Day 85 (missing)00112
PrimarySafety: Summary of the Induration Injection Site Reaction (SC Cohorts) Assessed in Participants

Induration was measured as the largest diameter across the needle site on the skin in millimetres (mm). This assessment was taken for only those participants in subcutaneously dosed treatment groups; 600 mg SC and 300 mg SC, anifrolumab and placebo. For the 300 mg SC anifrolumab and 300 mg SC placebo groups which received two simultaneous injections, the average of the two injection site diameters (mm) were reported.

Time frame:
Immediately after dosing, at 10, 20 minutes and 1 hour after injection
Reported as:
Mean · Millimeter
Safety: Summary of the Induration Injection Site Reaction (SC Cohorts) Assessed in Participants
MillimeterAnifrolumab 300 mg SC InjectionsAnifrolumab 600 mg SC InfusionPlacebo 300mg SC InjectionPlacebo 600 mg Anifrolumab SC
Immediately after dosing4.2 ± 10.2122.5 ± 13.690.0 ± 0.0012.5 ± 15.00
10 minutes after injection0.8 ± 2.0417.3 ± 12.390.0 ± 0.0016.5 ± 19.21
20 minute after injection0.1 ± 0.2014.1 ± 11.410.1 ± 0.258.0 ± 16.00
1 hour after injection0.0 ± 0.0011.7 ± 13.290.0 ± 0.0012.5 ± 25.00

Adverse events

Collected over From screening to final follow-up visit, up to 16 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Anifrolumab 300 mg SC Injections0/6 (0%)0/6 (0%)3/6 (50%)
Anifrolumab 300 mg IV Infusion0/6 (0%)0/6 (0%)2/6 (33.3%)
Placebo 300 mg Anifrolumab SC0/4 (0%)0/4 (0%)1/4 (25%)
Placebo 300 mg IV Infusion0/4 (0%)0/4 (0%)1/4 (25%)
Placebo 600 mg Anifrolumab (SC)0/4 (0%)0/4 (0%)2/4 (50%)
Anifrolumab 600 mg SC Infusion0/6 (0%)0/6 (0%)4/6 (66.7%)
Pooled Placebo0/12 (0%)0/12 (0%)4/12 (33.3%)
All Anifrolumab Subjects0/18 (0%)0/18 (0%)9/18 (50%)
Most frequent other events
Showing 10 of 20
Most frequent other events
EventAnifrolumab 300 mg SC InjectionsAnifrolumab 300 mg IV InfusionPlacebo 300 mg Anifrolumab SCPlacebo 300 mg IV InfusionPlacebo 600 mg Anifrolumab (SC)Anifrolumab 600 mg SC InfusionPooled PlaceboAll Anifrolumab Subjects
Upper respiratory tract infectionInfections and infestations2/61/60/40/40/40/60/123/18
Dry throatRespiratory, thoracic and mediastinal disorders0/62/60/40/40/40/60/122/18
Oral herpesInfections and infestations0/60/60/41/40/40/61/120/18
Peripheral swellingGeneral disorders0/60/61/40/40/40/61/120/18
HeadacheNervous system disorders1/60/60/40/41/40/61/121/18
Menstrual disorderReproductive system and breast disorders1/40/10/10/20/10/20/41/7
Dermatitis contactSkin and subcutaneous tissue disorders0/60/60/40/41/40/61/120/18
Tooth abscessInfections and infestations0/60/60/40/40/41/60/121/18
Tinea pedisInfections and infestations0/60/60/40/40/41/60/121/18
Abdominal discomfortGastrointestinal disorders1/60/60/40/40/40/60/121/18

Baseline characteristics

Thirty healthy male and female subjects were included in this study, 6 subjects per anifrolumab treatment (300 mg anifrolumab SC, 300 mg anifrolumab IV, 600 mg anifrolumab SC) and 12 subjects for placebo treatment.

Age, Continuous
Age, Continuous(Years)Anifrolumab 300 mg SC InjectionsAnifrolumab 300 mg IV InfusionAnifrolumab 600 mg SC InfusionPooled PlaceboTotal
Mean27.5 ± 6.8929.7 ± 7.9726.3 ± 6.6538.4 ± 12.2632.1 ± 10.62
Sex/Gender, Customized
Sex/Gender, Customized(Count of participants)Anifrolumab 300 mg SC InjectionsAnifrolumab 300 mg IV InfusionAnifrolumab 600 mg SC InfusionPooled PlaceboTotal
Female412411
Male254819
08

Study locations

1 site
  • Research Site
    Baltimore, Maryland 21225, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2015 to primary completion in May 2016, 6 months.

Results were first posted in Feb 2019, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2015
First posted
Nov 10, 2015
StartActual
Nov 16, 2015
Primary completionActual
May 25, 2016
CompletionActual
May 25, 2016
Results first posted
Feb 26, 2019
Last update
Feb 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02601625
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 10, 2015
Start date
Nov 16, 2015
Primary completion
May 25, 2016
Completion
May 25, 2016
Results posted
Feb 26, 2019
Last update
Feb 26, 2019

Study contacts

Ronald Goldwater, Dr.
principal investigator · PAREXEL Early Phase Clinical Unit, Baltimore, United States of America

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anifrolumab

Start the discussion